Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Mar;98(3):308-12; discussion 312-3.
doi: 10.1016/s0161-6420(91)32295-4.

MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors

E A Lippa  1 , J S Schuman, E J Higginbotham, M A Kass, R N Weinreb, G L Skuta, D L Epstein, B Shaw, D J Holder, D A Deasy, et al.
Affiliations
Clinical Trial

MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors

E A Lippa et al. Ophthalmology. 1991 Mar.

Abstract

Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary open-angle glaucoma or ocular hypertension. MK-507 was given every 8 or 12 hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

PubMed Disclaimer

LinkOut - more resources